TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Sponsor: Hope Biosciences LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$4,853,840

Rescue Site Savings

+$3,217,080

Unlock Full NCT06654193 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06654193 Rescue Dossier →